3rd Circ. Says Cash Not Key For Pay-For-Delay Suits

Law360, New York (June 26, 2015, 11:24 AM EDT) -- The Third Circuit ruled Friday that pharmaceutical patent settlements do not need to come in the form of a cash payout from a brand to a generic to face antitrust scrutiny as pay-for-delay agreements under U.S. Supreme Court precedent.

A three-judge panel overturned the dismissal of an antitrust suit by Louisiana Wholesale Drug Co. Inc. and King Drug Co. of Florence Inc. challenging a Hatch-Waxman Act settlement GlaxoSmithKline PLC signed with Teva Pharmaceutical Industries Ltd.

The plaintiffs maintained that GSK paid off Teva to delay launching...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.